期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 16, 期 5, 页码 241-245出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2016.01.008
关键词
Cardiopulmonary; Clinical trials; Multiple myeloma; Proteasome inhibitor; Review
资金
- Onyx/Amgen Inc.
Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent. (C) 2016 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据